KeyBioscience grants Lilly rights to Type II diabetes platform

The KeyBioscience AG subsidiary of Nordic Bioscience A/S (Herlev, Denmark) granted

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE